Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Monoclonal VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Research Question:
How well does a monoclonal antibody, "anti-SEMA4D monoclonal antibody VX15/2503," work in treating patients with stage I-III pancreatic cancer?

Basic Study Information

Purpose:
This randomized phase I trial studies how well a monoclonal antibody, anti-SEMA4D monoclonal antibody VX15/2503, works in treating patients with stage I-III pancreatic cancer. It will be used with or without another monoclonal antibody, ipilimumab or nivolumab. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

Location: University of Rochester Medical Center
Study Reference #: SGIM19105

Lead Researcher (Principal Investigator)

Lead Researcher:  David Linehan

Study Contact Information

Study Coordinator: Chris LeFeber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Return to Search